Home > Newsletters > FDAnews Device Daily Bulletin > Edwards 3Q Earnings Fall Short, Company Blames Medicare, Austerity
FDAnews Device Daily Bulletin
Oct. 19, 2012 | Vol. 9 No. 206
Edwards 3Q Earnings Fall Short, Company Blames Medicare, Austerity
Slowed uptake of the Sapien transcatheter heart valve led Edwards Lifesciences to issue advance warning last week of disappointing third-quarter sales. Edwards’ transcatheter heart valve sales dropped to $124 million globally and $55 million in the U.S., compared with $145 million and $62 million, respectively, in the second quarter.
Devices & Diagnostics Letter
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.